All Reports and Publications

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

All Reports and Publications

Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2024

Most Medicare Part D Plans’ Formularies Included Humira Biosimilars for 2025

Fewer than One in Five Medicare Enrollees Received Medication to Treat Their Opioid Use Disorder

Medicare Part D Spending for 10 Selected Diabetes Drugs Totaled $35.8 Billion in 2023, an Increase of 364 Percent From 2019

Medicare Contractors Did Not Use Complete and Timely Utilization Data When Making Part B Coverage Determinations for Stelara

Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2024

Not All Medicare Enrollees Are Continuing Treatment for Opioid Use Disorder

West Virginia Did Not Always Invoice Rebates to Manufacturers for Physician-Administered Drugs

How FDA Used Its Accelerated Approval Pathway Raised Concerns in 3 of 24 Drugs Reviewed

Update: Xolair Prefilled Syringes Likely Meet Part B Coverage Criteria

Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2024

Medicare Part D Paid Millions for Drugs for Which Payment Was Available Under the Medicare Part A Skilled Nursing Facility Benefit

Medicare and Medicaid Enrollees in Many High-Need Areas May Lack Access to Medications for Opioid Use Disorder

Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2022 Average Sales Prices

South Carolina Did Not Always Invoice Rebates to Manufacturers for Physician-Administered Drugs Dispensed to Enrollees of Medicaid Managed-Care Organizations

Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2024

Medicare and Some Enrollees Paid Substantially More When Stelara Was Covered Under Part D Versus Part B

Part D Plans Generally Include Drugs Commonly Used by Dual-Eligible Enrollees: 2024

Medicaid Managed Care: States Do Not Consistently Define or Validate Paid Amount Data for Drug Claims

State Agencies Could Be Obtaining Hundreds of Millions in Additional Medicaid Rebates Associated With Physician-Administered Drugs

All Reports and Publications

Filters